

Serial No. 09/194,889
October 20, 2000

-2-

TSRI 540.1

and remarks are respectfully submitted before any extension of time is incurred, thus making the present duplicate response a timely filing.

Reconsideration of this application and pending claims in view of the amendments and discussion below is respectfully requested.

IN THE CLAIMS

Please cancel claims 4, 5, 8-17, 32, 34 and 35.

Please amend claims 18 and 27:

(1)
but
B3
18. (Amended) A method for the treatment of a patient having obesity comprising the steps of:

(2)
but
B2
administering at least one therapeutic cytokine OB-R expression inducer; and
administering a physiologically effective amount of an OB-R agonist ligand.

(2)
27. (Amended) A method for the treatment of a patient [having a condition characterized by OB resistance] requiring induction of OB receptor expression, comprising the steps of:

(2)
but
B2
administering IL-6 in an amount from about 0.5 to about 20 micrograms per kilogram body weight; and

(2)
but
B2
administering recombinant human OB protein in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

REMARKS

Claims 1-3, 6, 7, 18-31, and 33 are now pending in view of the above amendments.
Applicants maintain that no new matter is presented by the above amendments.

The present response is believed to fully meet all of the objections and rejections set forth in the Action.

With regard to the comments, objections and rejections presented in the Action by the Examiner, Applicants' response continues below.